TOP2A and cancer: Given these former observations, a reappraisal of TOP2A expression in a well-defined cohort of PPGL with updated definitions of metastasis as per the 2022 WHO classification could be of potential clinical utility considering the strong association with worse outcome in addition to the ever-changing landscape of personalized cancer medicine and development of topoisomerase inhibitors in clinical practice.